Breast cancer targets

2011 Annual Report

Better breast cancer treatment, fewer side effects from targeted therapy

Dr. Peggy Porter

Dr. Peggy Porter

Cancer research takes teamwork, and few institutions know teamwork as well as the Hutchinson Center. That’s why the National Cancer Institute recently chose the Center to lead a five-year, Seattle-based breast cancer research consortium.

The consortium’s goal: to improve breast cancer prevention, detection, treatment and care for women who have or are at risk for the disease.

Led by the Hutchinson Center’s Drs. Peggy Porter and Mac Cheever, the Seattle Cancer Consortium Breast SPORE (Specialized Program in Research Excellence) involves 25 researchers from the Center and University of Washington as well as project consultants from institutions across the U.S. and abroad.

“The collaborations that have been formed among basic, clinical and translational scientists at the Hutchinson Center and University of Washington were key to landing the consortium,” Porter said.

Developing targeted breast cancer treatments is the unifying mission behind the consortium’s four scientific projects. Because targeted therapies zero in on specific molecules involved in tumor growth, they often have less severe side effects than standard chemotherapy and radiation.

“Our mission is to provide better breast cancer treatment options that are developed from the science at the Center and the UW,” Cheever said.